Loss of heterozygosity at 1p, 7q, 17p, and 22q in meningiomas

Journal of Korean Neurosurgical Society

Volumn 48, Issue 1, 2010, Pages 14-19

  Chang, Bok ^a   Cho, Byung Moon ^a   Moon, Seung Myung ^a   Park, Se Hyuck ^a   Oh, Sae Moon ^a   Cho, Seong Jin ^a  

^a Hallym University   (South Korea)

Author keywords

Chromosome; Loss of heterozygosity; Meningiomas

Indexed keywords

DNA;

ADULT; AGED; ANAPLASTIC CARCINOMA; BENIGN TUMOR; CANCER GRADING; CARCINOGENESIS; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 7Q; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; FEMALE; GENE LOCUS; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MEDICAL RECORD REVIEW; MENINGIOMA; MICROSATELLITE MARKER; REVIEW; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR GROWTH;

EID: 77957672673     PISSN: 20053711     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2010.48.1.14     Document Type: Review

References (34)

1. Akagi K, Kurahashi H, Arita N, Hayakawa T, Monden M, Mori T, et al.: Deletion mapping of the long arm of chromosome 22 in human meningiomas. Int J Cancer 60: 178-182, 1995
2. Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, et al.: Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94: 3210-3218, 2002
3. Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, Pang S, et al.: Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ 3: 11-20, 1992
4. Bozzetti C, Bortesi B, Merisio C: Loss of heterozygosity (LOH) in ovarian cancer. Int J Gynaecol Obstet 85: 294-295, 2004
5. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33, 1984
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991
7. Jeffers M, Rong S, Vande Woude GF: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16: 1115-1125, 1996
8. Karamitopoulou E, Perentes E, Diamantis I: p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol (Berl) 85: 611-616, 1993
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage.Cancer Res 51: 6304-6311, 1991
10. Kim JH, Lee SH, Rhee CH, Park SY, Lee JH: Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas. J Neurooncol 40: 101-106, 1998
11. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al.: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225; discussion 226-219, 2002
12. Lee JY, Finkelstein S, Hamilton RL, Rekha R, King JT Jr, Omalu B: Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery 55: 1163-1173, 2004
13. Lee SH, Kim JH, Rhee CH, Kang YS, Lee JH, Choi KS: Loss of heterozygosity on chromosome 10, 13, 17, and p53 gene mutation in human brain gliomas. J Korean Neurosurg Soc 22: 537-550, 1993
14. Leuraud P, Marie Y, Robin E, Huguet S, He J, Mokhtari K, et al.: Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas. J Neurooncol 50: 207-213, 2000
15. Liu Y: The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 215: 159-169, 1998
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007
17. Martínez-Rumayor A, Arrieta O, Guevara P, Escobar E, Rembao D, Salina C, et al.: Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett 213: 117-124, 2004
18. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K: Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6: 1313-1318, 1991
19. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13: 41-59, 2002
20. Moriyama T, Kataoka H, Kawano H, Yokogami K, Nakano S, Goya T, et al.: Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett 124: 149-155, 1998
21. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H, Steudel WI, Zang KD: Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol 56: 879-886, 1997
22. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al.: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989
23. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P: p53 mutations in nonastrocytic human brain tumors. Cancer Res 51: 6202-6205, 1991
24. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, et al.: Mechanism of met oncogene activation. Cell 45: 895-904, 1986
25. Patil SR, Merrick S, Lubs HA: Identification of each human chromosome with a modified Giemsa stain. Science 173: 821-822, 1971
26. Pykett MJ, Landers J, George DL: Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas. J Neurooncol 32: 39-44, 1997
27. Riemenschneider MJ, Perry A, Reifenberger G: Histological classification and molecular genetics of meningiomas. Lancet Neurol 5: 1045- 1054, 2006
28. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, et al.: Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 55: 4696-4701, 1995
29. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiesen T, et al.: Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 58: 3226-3230, 1998
30. Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T: Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59: 5995-5998, 1999
31. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al.: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 94: 14719-14724, 1997
32. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millasseau P, et al.: A second-generation linkage map of the human genome. Nature 359: 794-801, 1992
33. Zankl H, Zang KD: Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique. Humangenetik 14: 167-169, 1972
34. Zhou CZ, Qiu GQ, Zhang F, He L, Peng ZH: Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. World J Gastroenterol 10: 1431-1435, 2004